Actively Recruiting
Sentinel Lymph Node in Early-Stage Endometrium Cancer
Led by Istanbul University · Updated on 2024-11-25
100
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this prospective study is to investigate whether the detection rate of sentinel lymph node (SLN) with double tracer injected at two different sites may be increased compared to the standard use of a single tracer with single site (cervix) injection in early-stage endometrial cancer.
CONDITIONS
Official Title
Sentinel Lymph Node in Early-Stage Endometrium Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must have preoperative histologic diagnosis of endometrial carcinoma
- Must be in early stage (stage 1 and 2) endometrial carcinoma radiologically and clinically
- Must have written informed consent
You will not qualify if you...
- Possible allergic reaction to commonly used drugs
- Medical or surgical contraindications for comprehensive staging
- Preoperative or intraoperative findings of advanced endometrial cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Istanbul University Medical Faculty Dept. of Obstet Gynecol, Division of Gynecologic Oncology
Istanbul, Istanbul / Turkey, Turkey (Türkiye), 34093
Actively Recruiting
Research Team
M
Mustafa ALBAYRAK, MD
CONTACT
Y
Yagmur MİNARECİ, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here